Aromatase Inhibitor Musculoskeletal Syndrome and Bone Loss: a Review of the Current Literature

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomized trials. Lancet. 2015;386(10001):1341–52.

Article  Google Scholar 

Xu X, Chlebowski RT, Shi J, Barac A, Haque R. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. Breast Cancer Res Treat. 2019;174:785–94.

Article  CAS  PubMed  Google Scholar 

Wagner LI, Zhao F, Goss PE, Chapman JW, Shepherd LE, Whelan TJ, Mattar BI, Bufill JA, Schultz WC, LaFrancis IE, Nagargoje GG, Vemuri R, Nikcevich DA, Sledge GW, Cella D. Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC. Clinical Trials Group Breast Cancer Res Treat. 2018;169(3):537.

Article  CAS  Google Scholar 

Presant CA, Bosserman L, Young T, Vakil M, Horns R, Upadhyaya G, Ebrahimi B, Yeon C, Howard F. Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer. 2007;7(10):775–8.

Article  CAS  PubMed  Google Scholar 

Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. AM J Clin Oncol. 2012;30(9):936–42.

Article  CAS  Google Scholar 

• Tenti S, Correale P, Cheleschi S, Fioravanti A, Pirtoli L. Aromatase inhibitors-induced musculoskeletal disorders: current knowledge on clinical and molecular aspects. Int J Mol Sci. 2020;21(16):5625. This study has an up to date review on aromatase inhibitors effect on musculoskeletal syndromes and current understanding of mechanisms.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Hyder T, Marino CC, Ahmad S, Nasrazadani A, Brufsky AM. Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management. Front Endocrinol (Lausanne). 2021;27(12):713700. This article discusses proposed criteria for aromatase inhibitor arthralgia and gives a good overview of the current knowledge of the condition.

Article  Google Scholar 

Niravath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol. 2013;24(6):1443–9.

Article  CAS  PubMed  Google Scholar 

Din O, Dodwell D, Wakefield R, et al. Aromatase inhibitor induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat. 2010;120:525–38.

Article  CAS  PubMed  Google Scholar 

Morales L, Pans S, Paridaens R, et al. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat. 2007;104:87–91.

Article  CAS  PubMed  Google Scholar 

Bruzzese V, Hassan C, Zullo A, Zampa G. Rheumatoid arthritis: a complication of aromatase inhibitor therapy? Int J Immunopathol Pharmacol. 2011;24:1099–101.

Article  CAS  PubMed  Google Scholar 

Bertolini E, Letho-Gyselinck H, Prati C, Wendling D. Rheumatoid arthritis and aromatase inhibitors. Jt Bone Spine. 2011;78:62–4.

Article  CAS  Google Scholar 

Chao J, Parker BA, Zvaifler NJ. Accelerated cutaneous nodulosis associated with aromatase inhibitor therapy in a patient with rheumatoid arthritis. J Rheumatol. 2009;36:1087–8.

Article  PubMed  Google Scholar 

Caprioli M, Carrara G, Sakellariou G, Silvagni E, Scirè CA. Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology. RMD Open. 2017;3(2):e000523.

Article  PubMed  PubMed Central  Google Scholar 

Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, et al. Risk factors for joint symptoms in patients enrolled in the atac trial: a retrospective, exploratory analysis. Lancet Oncol. 2008;9(9):866–72.

Article  PubMed  Google Scholar 

Yardley DA. Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptorpositive breast cancer. Breast Cancer (Dove Med Press). 2016;8:73–82.

CAS  PubMed  Google Scholar 

Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer. 2009;115(16):3631–9.

Article  CAS  PubMed  Google Scholar 

Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26(7):1051–7.

Article  CAS  PubMed  Google Scholar 

De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATAGIM3): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):474–85.

Article  PubMed  Google Scholar 

Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. ESMO Guidelines Working Group. Bone health in cancer patients: ESMO clinical practice guidelines. ANN Oncol. 2014;25:124–37.

Article  Google Scholar 

Pedersini R, Amoroso V, Maffezzoni F, Gallo F, Turla A, Monteverdi S, Ardine M, Ravanelli M, Vassalli L, Rodella F, et al. Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy. JAMA Netw Open. 2019;2:e1911080.

Article  PubMed  PubMed Central  Google Scholar 

• Chung KY, Ho G, Novak CB, Baltzer HL. Aromatase inhibitor-induced carpal tunnel syndrome and stenosing tenosynovitis: a systematic review. Plast Reconstr Surg. 2022;149(3):445e–52e. This is the most up to date reference regarding carpal tunnel syndrome associated with aromatase inhibitors.

Article  CAS  PubMed  Google Scholar 

Shin DJ, Nam KE, Song DH, Im S, Won SJ, Kim YH, Lim SH, Lee JI. Carpal tunnel syndrome and tenosynovitis in women with breast cancer associated with hormone therapy: a multi-institutional analysis using a clinical data warehouse. Medicine (Baltimore). 2022;101(5):e28786.

Article  PubMed  Google Scholar 

Sheng JY, Blackford AL, Bardia A, Venkat R, Rosson G, Giles J, Hayes DF, Jeter SC, Zhang Z, Hayden J, Nguyen A, Storniolo AM, Tarpinian K, Henry NL, Stearns V. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy. Breast Cancer Res Treat. 2019;176(3):617–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mitsimponas N, Klouva E, Tryfonopoulos D, Grivas A, Demiri S, Koumakis G, Gouveris P. Aromatase inhibitor-associated tendinopathy and muscle tendon rupture: report of three cases of this exceedingly rare adverse event. Case Rep Oncol. 2018;11(2):557–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martens HA, Schröder CP, van der Eerden PJ, Willemse PH, Posthumus MD. Severe disabling tendinopathy caused by anastrazole. Rheumatology (Oxford). 2007;46(10):1619–21.

Article  CAS  PubMed  Google Scholar 

Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the (articular tolerance of letrozole) study. Breast Cancer Res Treat. 2010;120(1):127–34.

Article  CAS  PubMed  Google Scholar 

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(1):127–38.

Article  CAS  PubMed  Google Scholar 

Arem H, Sorkin M, Cartmel B, Fiellin M, Capozza S, Harrigan M, Ercolano E, Zhou Y, Sanft T, Gross C, Schmitz K, Neogi T, Hershman D, Ligibel J, Irwin ML. Exercise adherence in a randomized trial of exercise on aromatase inhibitor arthralgias in breast cancer survivors: the hormones and physical exercise (HOPE) study. J Cancer Surviv. 2016;10(4):654–62.

Article  PubMed  PubMed Central  Google Scholar 

• Boing L, Vieira MCS, Moratelli J, Bergmann A, Guimarães ACA. Effects of exercise on physical outcomes of breast cancer survivors receiving hormone therapy - a systematic review and meta-analysis. Maturitas. 2020;141:71–81. This article reviews the most recent review on exercise treatment for aromatase inhibitor musculoskeletal syndrome.

Article  CAS  PubMed  Google Scholar 

Paulo TRS, Rossi FE, Viezel J, Tosello GT, Seidinger SC, Simões RR, de Freitas R Jr, Freitas IF Jr. The impact of an exercise program on quality of life in older breast cancer survivors undergoing aromatase inhibitor therapy: a randomized controlled trial. Health Qual Life Outcomes. 2019;17(1):17.

Article  PubMed  PubMed Central  Google Scholar 

•• Roberts KE, Adsett IT, Rickett K, Conroy SM, Chatfield MD, Woodward NE. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer. Cochrane Database Syst Rev. 2022;1(1):CD013167. The most up to date review of the literature on the prevention and treatment of AIMSS.

PubMed  Google Scholar 

• Zhu XY, Li Z, Chen C, Feng RL, Cheng BR, Liu RY, Wang RT, Xu L, Wang Y, Tao X, Zhao P. Physical therapies for psychosomatic symptoms and quality of life induced by aromatase inhibitors in breast cancer patients: a systematic review and meta-analysis. Front Oncol. 2021;11:745280. Another good review of current exercise therapies for AIMSS.

Article  PubMed  PubMed Central  Google Scholar 

Kubo M, Onishi H, Kuroki S, Okido M, Shimada K, Yokohata K, et al. Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Res. 2012;32(6):2331–6.

CAS  PubMed  Google Scholar 

Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, Sharer CW, Burton GV, Kuzma CS, Moseley A, Lew DL, Fisch MJ, Moinpour CM, Hershman DL, Wade JL 3rd. Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202. J Clin Oncol. 2018;36(4):326.

Article  CAS 

留言 (0)

沒有登入
gif